Dow opens above 23,000, powered by IBM
October 18, 2017IBM shares head for biggest gain in eight years
October 18, 2017Allergan ruling casts doubt on tribal patent strategy
at
(Reuters) – A U.S. judge’s ruling on Monday invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.
Powered by WPeMatico
